黑人前列腺癌患者慎用ADT疗法治疗

2016-08-19 MedSci MedSci原创

一项回顾性研究指出,患有进展性前列腺癌的黑人在接受放疗前若采用短期ADT治疗,各种原因死亡的风险较其他种族的民众而言增加77%。研究结果发表在Cancer。波士顿布莱根妇女医院放射肿瘤科的Konstantin A. Kovtun博士指出,医生应尽量避免患侵袭性前列腺癌的美洲和非洲民众采用ADT治疗。对于任何种族、任何肤色的前列腺癌患者而言,医生一般不会采取ADT +放疗的方法进行治疗,因为该方法并

一项回顾性研究指出,患有进展性前列腺癌的黑人在接受放疗前若采用短期ADT治疗,各种原因死亡的风险较其他种族的民众而言增加77%。研究结果发表在Cancer


波士顿布莱根妇女医院放射肿瘤科的Konstantin A. Kovtun博士指出,医生应尽量避免使患侵袭性前列腺癌的美洲和非洲民众采用ADT治疗。对于任何种族、任何肤色的前列腺癌患者而言,医生一般不会采取ADT +放疗的方法进行治疗,因为该方法并不改善患者的生存率,而且有证据表明,这种方法可能对黑人男性更为不利。 

非洲裔和美洲裔的前列腺癌患者接受这项为期4个月的激素治疗的目的是将前列腺缩小以达到放疗的目的。但是数据显示非洲裔和美洲裔的黑人男性较其他种族的男性患者死亡率较高。

研究人员对芝加哥前列腺癌中心7252名肿瘤侵袭性较低或中度的前列腺癌患者进行了调查,他们在1997年-2013年接受了放疗治疗,其中20%的患者接受了ADT疗法。研究人员对参与者进行了为期8年的随访,其中869名(12.0%)男性死亡,48名(5.52%)死于前列腺癌,其余821名(94.48%)死于其他原因。研究显示,黑色人种的全因死亡率明显增加,二者有明显关联(aHR:1.77;95%CI:1.06-2.94;P=0.028)。 

Kovtun博士和同事指出,ADT疗法+放疗不能显著提高患者的生存率,但是许多医院和随机临床试验仍然在用。对于侵袭性前列腺癌患者,使用ADT疗法或许会增加患者的副作用,导致更多并发症的出现,例如出现毒性反应导致患者出现心梗的风险增加,进而缩短患者的生存时间。但ADT疗法的好处在于可治疗机体出现的潜在疾病。

Kovtun博士和同事指出,需要进行更进一步的研究以从基因角度分析黑人和其他人种的差异原因。也需要进行利弊分析,评估患者是否有采用ADT疗法治疗的必要。

研究显示,男性前列腺癌患者接受ADT疗法后全因死亡率明显增加,除前列腺癌外的其他原因死亡率也是如此(aHR:1.86,95%CIl:1.08-3.19,P=0.024)。但是对于未接受ADT疗法的黑人患者而言,则未表现出这种关联(全因死亡率aHR:1.33,95%CI:0.93-1.91, P=0.12;其他原因死亡率aHR:1.39,95% CI:0.96-2.02,P =0.08)。

且研究人员指出,黑人的随访时间相比其他种族的患者而言明显缩短(6.12:9.62年)。因此研究人员对接受ADT疗法的黑人死亡率掌握的信息有限,但是这毫无疑问显示出接受ADT疗法的黑人男性死亡率明显增加。

那么问题来了,为什么前列腺癌黑人接受ADT疗法后死亡率增加?研究人员指出,或许由于黑人出现代谢性疾病的风险更高。但是他们表示仍需进行更进一步的研究。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2029614, encodeId=e3f020296146f, content=<a href='/topic/show?id=9360202054' target=_blank style='color:#2F92EE;'>#ADT疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2020, encryptionId=9360202054, topicName=ADT疗法)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Sat Dec 31 07:17:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104311, encodeId=244410431157, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 10:56:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=103978, encodeId=a78b1039e8c4, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 01:01:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102499, encodeId=bd07102499ab, content=阅读了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Tue Aug 23 08:57:00 CST 2016, time=2016-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477962, encodeId=f38214e7962de, content=<a href='/topic/show?id=dd832018bd' target=_blank style='color:#2F92EE;'>#ADT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2018, encryptionId=dd832018bd, topicName=ADT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87be7387847, createdName=124984e7m85暂无昵称, createdTime=Sun Aug 21 06:17:00 CST 2016, time=2016-08-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2029614, encodeId=e3f020296146f, content=<a href='/topic/show?id=9360202054' target=_blank style='color:#2F92EE;'>#ADT疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2020, encryptionId=9360202054, topicName=ADT疗法)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Sat Dec 31 07:17:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104311, encodeId=244410431157, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 10:56:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=103978, encodeId=a78b1039e8c4, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 01:01:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102499, encodeId=bd07102499ab, content=阅读了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Tue Aug 23 08:57:00 CST 2016, time=2016-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477962, encodeId=f38214e7962de, content=<a href='/topic/show?id=dd832018bd' target=_blank style='color:#2F92EE;'>#ADT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2018, encryptionId=dd832018bd, topicName=ADT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87be7387847, createdName=124984e7m85暂无昵称, createdTime=Sun Aug 21 06:17:00 CST 2016, time=2016-08-21, status=1, ipAttribution=)]
    2016-08-26 李东泽

    这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2029614, encodeId=e3f020296146f, content=<a href='/topic/show?id=9360202054' target=_blank style='color:#2F92EE;'>#ADT疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2020, encryptionId=9360202054, topicName=ADT疗法)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Sat Dec 31 07:17:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104311, encodeId=244410431157, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 10:56:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=103978, encodeId=a78b1039e8c4, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 01:01:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102499, encodeId=bd07102499ab, content=阅读了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Tue Aug 23 08:57:00 CST 2016, time=2016-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477962, encodeId=f38214e7962de, content=<a href='/topic/show?id=dd832018bd' target=_blank style='color:#2F92EE;'>#ADT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2018, encryptionId=dd832018bd, topicName=ADT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87be7387847, createdName=124984e7m85暂无昵称, createdTime=Sun Aug 21 06:17:00 CST 2016, time=2016-08-21, status=1, ipAttribution=)]
    2016-08-26 李东泽

    这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2029614, encodeId=e3f020296146f, content=<a href='/topic/show?id=9360202054' target=_blank style='color:#2F92EE;'>#ADT疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2020, encryptionId=9360202054, topicName=ADT疗法)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Sat Dec 31 07:17:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104311, encodeId=244410431157, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 10:56:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=103978, encodeId=a78b1039e8c4, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 01:01:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102499, encodeId=bd07102499ab, content=阅读了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Tue Aug 23 08:57:00 CST 2016, time=2016-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477962, encodeId=f38214e7962de, content=<a href='/topic/show?id=dd832018bd' target=_blank style='color:#2F92EE;'>#ADT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2018, encryptionId=dd832018bd, topicName=ADT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87be7387847, createdName=124984e7m85暂无昵称, createdTime=Sun Aug 21 06:17:00 CST 2016, time=2016-08-21, status=1, ipAttribution=)]
    2016-08-23 刘煜

    阅读了。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2029614, encodeId=e3f020296146f, content=<a href='/topic/show?id=9360202054' target=_blank style='color:#2F92EE;'>#ADT疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2020, encryptionId=9360202054, topicName=ADT疗法)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Sat Dec 31 07:17:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104311, encodeId=244410431157, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 10:56:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=103978, encodeId=a78b1039e8c4, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 01:01:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102499, encodeId=bd07102499ab, content=阅读了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Tue Aug 23 08:57:00 CST 2016, time=2016-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477962, encodeId=f38214e7962de, content=<a href='/topic/show?id=dd832018bd' target=_blank style='color:#2F92EE;'>#ADT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2018, encryptionId=dd832018bd, topicName=ADT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87be7387847, createdName=124984e7m85暂无昵称, createdTime=Sun Aug 21 06:17:00 CST 2016, time=2016-08-21, status=1, ipAttribution=)]

相关资讯

Clin Nutr:番茄能降低前列腺癌患者的前列腺特异性抗原(PSA)水平

目的:含番茄红素的食品在前列腺癌发展中的作用尚不清楚。我们进行了研究探究番茄红素丰富的番茄干预能否降低前列腺癌患者的前列腺特异性抗原(PSA)水平。方法:在治疗前将79名前列腺癌患者被随机分配到以下营养干预组:每一天含30毫克番茄红素的番茄产品;番茄制品+硒、ω-3脂肪酸、大豆异黄酮、葡萄/石榴汁和绿茶/红茶(番茄+其他);对照组。进行长达3周的研究。结果:干预组和对照组的PSA值变化没有差异。根

Lancet:机器人辅助腹腔镜前列腺切除术vs开放性耻骨后前列腺根治切除术

缺乏机器人辅助腹腔镜前列腺切除术和开放耻骨后前列腺根治切除术的实验数据比较是泌尿肿瘤学领域的重要知识缺口。我们旨在比较这两种方法的功能预后和肿瘤结局及术后12周时的早期结局。

Cell:组学“全景”分析推动前列腺癌精准治疗

最近来自美国UCLA的癌症研究人员开发了一组复杂的分析工具对患有转移性前列腺癌的病例进行分析,绘制了帮助前列腺癌细胞增殖和抵抗治疗的复杂基因和蛋白质网络的详细图谱。研究人员还开发了一种计算方法来分析病人个体化数据帮助每位病人选择最有效的治疗药物。相关研究结果发表在国际学术期刊Cell上。研究人员首先对活检获得的转移性前列腺癌病人的组织样本进行了一系列复杂分析,并且对每个病人癌细胞的描述达到了前所未

2016年前列腺癌重大指南研究进展回顾

近期前列腺癌研究领域的大量基础和临床研究,从不同方向、不同角度对前列腺癌及其并发症的临床诊治进行了深入研究,为前列腺癌的临床管理寻找最新方向。本文就近期前列腺癌领域重要的指南共识方面进行回顾。一、重要指南1,中国去势抵抗性前列腺癌诊治专家共识前列腺癌是欧美国家男性发病率最高的恶性肿瘤。而在中国,其发病率也逐年升高。据估计,2015年我国前列腺癌新发病例有60 300例,死亡病例约26 600例

NEJM:前列腺癌遗传性DNA修复基因突变谱被揭示,复杂度超出想象

7月6日华盛顿大学的科学家们在《新英格兰医学》(NEJM)上发表了一项前列腺癌研究,认为DNA修复基因的遗传性突变在转移性前列腺癌中相当普遍。这些突变对转移性前列腺癌做出的贡献比人们想象的更为广泛,超过10%的人群,这从另一角度也显示出转移性前列腺癌的复杂性和异质性。 在总计7个系列研究,合计692位转移性前列腺癌患者中,超过10% (82位)的侵袭性前列腺癌男性患者,携带DNA